(Q37074153)

18 August 2017

1 reference

title

Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when (English)

1 reference

18 August 2017

1 reference

1 reference

1 reference

Ian N Olver

1

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

125-131

1 reference

Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Brain metastases: the HER2 paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.125

21 January 2018

Identifiers

DOI

10.2217/14796694.4.1.125

1 reference

18 August 2017

1 reference